Drug Profile
Research programme: extended release antipsychotic therapeutics - Alkermes
Alternative Names: ALKS-7921; Olanzapine extended-releaseLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Alkermes
- Developer Alkermes plc
- Class Piperazines; Quinolines
- Mechanism of Action 5-HT1A serotonin receptor agonists; Dopamine receptor agonists; Dopamine receptor antagonists; Serotonin 2A receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Psychotic disorders; Schizophrenia
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Psychotic-disorders in USA (Parenteral, Injection)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Schizophrenia in USA (Parenteral, Injection)
- 16 Sep 2011 Elan Drug Technologies has merged with Alkermes Inc to form Alkermes plc